| Matthew James Mason, MD | |
|
200 W Arbor Dr, San Diego, CA 92103-9000 | |
| (800) 926-8273 | |
| Not Available |
| Full Name | Matthew James Mason |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 200 W Arbor Dr, San Diego, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487116281 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A179571 (California) | Primary |
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578672184 PECOS PAC ID: 3577476761 Enrollment ID: O20031211000464 |
News Archive
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.
"More than 40 percent of employers surveyed by the consulting firm Mercer expect health care reform to raise health care costs by a modest 2 percent or less next year," the Associated Press reports.
Celsion Corporation has announced that promising Phase I clinical results evaluating ThermoDox for the treatment of recurrent chest wall (RCW) breast cancer were presented by Duke University investigators on Sunday, April 5 at the 2009 Annual Meeting of the Society for Thermal Medicine (STM) in Tucson, Arizona.
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer and Nycomed, a privately owned pharmaceutical company, today announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD.
Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has been accepted for formal review.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew James Mason, MD 5076 Long Branch Ave, San Diego, CA 92107-2006 Ph: (757) 434-3151 | Matthew James Mason, MD 200 W Arbor Dr, San Diego, CA 92103-9000 Ph: (800) 926-8273 |
News Archive
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.
"More than 40 percent of employers surveyed by the consulting firm Mercer expect health care reform to raise health care costs by a modest 2 percent or less next year," the Associated Press reports.
Celsion Corporation has announced that promising Phase I clinical results evaluating ThermoDox for the treatment of recurrent chest wall (RCW) breast cancer were presented by Duke University investigators on Sunday, April 5 at the 2009 Annual Meeting of the Society for Thermal Medicine (STM) in Tucson, Arizona.
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer and Nycomed, a privately owned pharmaceutical company, today announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD.
Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has been accepted for formal review.
› Verified 4 days ago
Sarah Wilkinson, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 W Arbor Dr # 8819, San Diego, CA 92103 Phone: 956-458-9885 | |
Dr. Ramandeep Singh Dhillon, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5454 El Cajon Blvd, San Diego, CA 92115 Phone: 619-515-2400 | |
Mina Kyrollus Ghobrial, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 200 W Arbor Dr, San Diego, CA 92103 Phone: 800-926-8273 Fax: 888-539-8781 | |
Dr. Timothy Stuart Hinman, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2001 4th Ave, San Diego, CA 92101 Phone: 858-499-2600 | |
Dr. Peter D. Aldrich, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 15025 Innovation Dr, San Diego, CA 92128 Phone: 858-554-8638 | |
Dr. Matthew J. Perl, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 15004 Innovation Dr, San Diego, CA 92128 Phone: 858-605-7171 | |
Jeffrey Adam Bush, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 4647 Zion Ave, San Diego, CA 92120 Phone: 619-528-5000 |